ClinicalTrials.gg
RecruitingNCT05716100Updated Nov 2, 2026

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

A Phase 3 interventional study of XEN1101 and Placebo in Focal Onset Seizures, sponsored by Xenon Pharmaceuticals Inc.. Recruiting at 103 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Nov 2, 2026First site in JapanSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Planned enrollment
28th of 306
360 · median 56
Started
2023
with 16 others
Phase 3
84 of 395
15 open now
Primary completion
2028-01
later than 53 of 91 live
Registered
327th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 28th largest by planned enrollment of the 306 interventional ones that give a count, is one of 17 that started in 2023, is one of 84 in phase 3, reaches primary completion later than 53 of the 91 other live ones, and was the 327th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

Read the detailed description

Approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo). Eligible subjects will have up to 9.5 weeks of baseline to assess frequency of seizures, followed by 12 weeks of blinded treatment. In order to be included in the study, subjects must be treated with a stable dose of 1 to 3 allowable antiseizure medications (ASMs) for at least one month prior to screening, during baseline, and throughout the double-blind treatment period (DBP) of the study. During the DBP, subjects will be instructed to orally take XEN1101 or placebo once daily with an evening meal.

Subjects who complete the 12-week DBP will have the opportunity to qualify and enroll in a separate open-label extension (OLE) study for continued treatment with XEN1101. Subjects who do not enroll in the OLE will enter a 8-week post treatment follow-up period.

03

Conditions studied

  • Focal Onset Seizures

Keywords

  • Epilepsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be properly informed of the nature and risks of the study and give in writing, prior to entering the study
  • Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy (2017). Subject must have had adequate trials of at least 2 ASMs, which were given (and tolerated) at adequate therapeutic doses, without achieving sustained seizure freedom.
  • Treatment with a stable dose of 1 to 3 allowable current ASMs for at least one month prior to screening, during baseline, and throughout the duration of the DBP
  • Able to keep accurate seizure diaries

Exclusion criteria

Exclusion Criteria:

  • Previously documented electroencephalogram which shows any pattern not consistent with focal etiology of seizures.
  • History of focal aware non-motor seizures only, non-epileptic psychogenic seizure, primary generalized seizure, developmental and epileptic encephalopathy, including Lennox-Gastaut syndrome.
  • Seizures secondary to drug or alcohol use, ongoing infection, neoplasia, demyelinating disease, degenerative neurological disease, metabolic illness, progressive structural lesion, encephalopathy, or progressive central nervous system (CNS) disease.
  • History of status epilepticus or repetitive seizures within the 12-month period preceding Visit 1 where the individual seizures cannot be counted.
  • History of neurosurgery for seizures \<1 year prior to Visit 1, or radiosurgery \<2 years prior to enrollment.
  • Any medical condition or personal circumstance that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study or prevents adherence to the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    XEN1101 25 mg/day

    XEN1101 25 mg/day

    Drug: XEN1101

  • Experimental
    XEN1101 15 mg/day

    XEN1101 15 mg/day

    Drug: XEN1101

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • XEN1101 Capsules

    Also known as: Azetukalner

  • DrugPlacebo

    Placebo Capsules

06

What researchers measure

Primary outcomes

  1. Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo.

    Time frame: From baseline through to the double blind period (week 12).

Secondary outcomes

  1. Proportion of subjects experiencing ≥50% reduction in focal seizure frequency from baseline through the DBP for XEN1101 versus placebo.

    Time frame: From baseline through to the double blind period (week 12).

  2. MPC in weekly (7 days) focal seizure frequency from baseline to Week 1 for XEN1101 versus placebo.

    Time frame: From baseline through to the week 1.

  3. Proportion of subjects experiencing "at least much improved" (including "much" and "very much improved") in Patient Global Impression of Change (PGI-C).

    Time frame: From baseline through to the double blind period (week 12).

  4. To assess adverse events as criteria for safety and tolerability of XEN1101.

    Time frame: From screening through to 56 days post-final dose

07

Study locations

63 of 103 sites recruiting
  • Clinical Trials, Inc.
    Little Rock, Arkansas 72205, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Rancho Research Institute
    Downey, California 90242, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of California Los Angeles (UCLA)
    Los Angeles, California 90095, United States
    Recruiting
  • University of California Irvine Health
    Orange, California 92868, United States
    Recruiting
  • Panhandle Research and Medical Clinic
    Gulf Breeze, Florida 32651, United States
    Recruiting
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
    Recruiting
  • Consultants in Epilepsy and Neurology, PLLC
    Boise, Idaho 83702, United States
    Recruiting
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62794, United States
    Recruiting
  • Mid-Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland 20817, United States
    Recruiting
  • 9D University Health Center
    Detroit, Michigan 48201, United States
    Recruiting
  • Northeast Regional Epilepsy Group
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Five Towns Neuroscience Research
    Woodmere, New York 11598, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Duke University Clinic
    Durham, North Carolina 27705, United States
    Recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
  • OhioHealth
    Columbus, Ohio 43214, United States
    Recruiting
  • Providence Neurological Specialities
    Portland, Oregon 97225, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
  • Austin Epilepsy Care Center
    Austin, Texas 78758, United States
    Recruiting
  • University of Utah Clinical Neurosciences Center
    Salt Lake City, Utah 84132, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Ramos Mejia
    Buenos Aires, 1221, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital De Alta Complejidad en Red el Cruce
    Buenos Aires, 1888, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Policlinico Lomas
    Buenos Aires, B1832BQD, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto de Neurologia Cognitiva (INECO)
    Buenos Aires, C1060AAF, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Italiano
    Buenos Aires, C1199ABB, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Britanico de Buenos Aires
    Buenos Aires, C1280AEB, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • STAT Resarch S.A.
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CENyR Centro de Especialidades Neurologicas y Rehabilitacion
    C.a.b.a., C1424, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • FLENI
    C.a.b.a., C1428DGG, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Córdoba
    Córdoba, X5000, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Central Ramon Carrilo
    San Luis, 5701, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sanatori del Sur S.A.
    San Miguel de Tucumán, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Alfred Hospital
    Melbourne, Victoria 30004, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Austin Health
    Melbourne, Victoria 3084, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Royal Melbourne Hospital
    Melbourne, 3050, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital Innsbruck
    Innsbruck, Austria
    Recruiting
  • Universitätsklinik für Neurologie
    Salzburg, 5020, Austria
    Recruiting
  • Medical University of Vienna
    Vienna, 1090, Austria
    Recruiting
  • Cliniques Universitaires Saint-Luc (UCL)
    Brussels, 1200, Belgium
    Recruiting
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
    Recruiting
  • MHATNPsy Sveti Naum EAD
    Sofia, 1113, Bulgaria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Medical center OPHTHA-NEURO
    Sofia, 1172, Bulgaria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinica Universidad de Los Andes
    Santiago, 7620157, Chile
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centro de Investigacion Clinica UC
    Santiago, 833073, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CINSAN
    Santiago, 8431657, Chile
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Clínico Viña del Mar
    Viña del Mar, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital Center Osijek
    Osijek, 31000, Croatia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinical Hospital Center Rijeka, Klinika za Neurologiju
    Rijeka, 51000, Croatia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Poliklinika Bonifarm
    Zagreb, 10000, Croatia
    Recruiting
  • University Hospital Center Zagreb
    Zagreb, 10000, Croatia
    Recruiting
  • Poliklinika LF MEDICAL
    Zagreb, 1000, Croatia
    Recruiting
  • EUC Hradec Kralove Clinic
    Hradec Králové, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Nemocnicni lekarna FN Motol / Motol University Hospital
    Prague, 150 06, Czechia
    Recruiting
  • Forbeli s.r.o.
    Prague, Czechia
    Recruiting
  • Kuopio University Hospital
    Kuopio, 70210, Finland
    Recruiting
  • Hopital Neurologique Pierre Wertheimer
    Bron, 69500, France
    Recruiting
  • Centre Hospitalier Universitaire de Lille (CHU de Lille)
    Lille, 59037, France
    Recruiting
  • Hôpital de la Pitié Salpêtrière
    Paris, 75013, France
    Recruiting
  • Hôpital Fondation A. de Rothschild
    Paris, 75019, France
    Recruiting
  • Chu de Rennes Hôpital Pontchaillou
    Rennes, 35033, France
    Recruiting
  • Hôpital de Hautepierre
    Strasbourg, 67098, France
    Recruiting
  • Universitätsklinikum Aachen
    Aachen, D-52074, Germany
    Recruiting
  • Krankenhaus Mara gGmbH
    Bielefeld, 33617, Germany
    Recruiting
  • University Hospital Frankfurt, ZNN - Epilepsy Center Frankfurt Rhine-Main
    Frankfurt, 60528, Germany
    Recruiting
  • Semmelweis Egyetem, Idegsebészeti és Neurointervenciós Klinika
    Budapest, 1145, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
    Recruiting
  • The Chaim Sheba Medical Center
    Ramat Gan, 6265601, Israel
    Recruiting
  • Kaplan Medical Center
    Rehovot, 76100, Israel
    Recruiting
  • The Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
    Recruiting
  • Ospedali Riuniti di Ancona
    Ancona, 60126, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Università degli studi di Bari Aldo Moro
    Bari, 70124, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Itami City Hospital
    Itami, Hyōgo 664-8540, Japan
    Recruiting
  • Seirei Mikatahara General Hospital
    Hamamatsu, Shizuoka 433-8558, Japan
    Recruiting
  • Hiroshima University Hospital
    Hiroshima, 498823, Japan
    Recruiting
  • Tanaka Neurosurgery & Headache Clinic
    Kagoshima, 890-0052, Japan
    Recruiting
  • Kyoto University Hospital
    Kyoto, 606-8507, Japan
    Recruiting
  • National Hospital Organization Nishiniigata Chuo Hospital
    Niigata, 950-2085, Japan
    Recruiting
  • Tokushima University Hospital
    Tokushima, 770-8503, Japan
    Recruiting
  • Institute of Science Tokyo Hospital
    Tokyo, 113-8519, Japan
    Recruiting
  • Grupo Medico Camino
    Benito Juárez, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Human Science Research Trials
    Mexico City, 14050, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Axis Heilsa S. de R.L. de C.V. Althian
    Monterrey, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurocencias Esudios Clinicos S.C.
    Sinaloa, 80020, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kempenhaeghe
    Heeze, Netherlands
    Recruiting
  • COPERNICUS Podmiot Leczniczy
    Gdansk, Poland
    Recruiting
  • NZOZ Neuromed M. i M. Nastaj Sp. P.
    Lublin, 20-064, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Twoja Przychodnia Nowosolskie Centrum Medyczne
    Nowa Sól, 67-100, Poland
    Recruiting
  • MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
    Recruiting
  • Neurosphera Sp. z o.o.
    Warsaw, 02-829, Poland
    Recruiting
  • Centro Hospitalar Universitário de Coimbra - CHUC
    Coimbra, Portugal
    Recruiting
  • Hospital da Senhora da Oliveira
    Guimarães, 4835-044, Portugal
    Recruiting
  • Centro Hospitalar de Lisboa Norte
    Lisbon, 1649-035, Portugal
    Recruiting
  • Centro Hospitalar Lisboa Ocidental
    Lisbon, Portugal
    Recruiting
  • Centro Hospitalar Universitário de Santo António
    Porto, 4099-001, Portugal
    Recruiting
  • Hospital Pedro Hispano
    Porto, 4464-513, Portugal
    Recruiting
  • Centro Hospitalar de Entre o Douro e Vouga
    Santa Maria da Feira, 520-211, Portugal
    Recruiting
  • ULS de Trás-os-Montes e Alto Douro
    Vila Real, 5000-508, Portugal
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Universitario Cruces
    Barakaldo, 48903, Spain
    Recruiting

Showing the first 100 of 103 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jan 2028, 56 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's planned 56 months is close to that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Oct 2026 → Jan 2028 and completion Dec 2026 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 8, 2023
StartActual
May 9, 2023
Primary completionEst.
Jan 2028was Oct 2026
CompletionEst.
Mar 2028was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added — first site in Japan. 4 sites changed recruiting status (4 now withdrawn)
Show 4 sites
  • Clinical Trials, Inc. · Little Rock, United StatesRecruiting→Withdrawn
  • Rancho Research Institute · Downey, United StatesRecruiting→Withdrawn
  • Università degli studi di Bari Aldo Moro · Bari, ItalyRecruiting→Withdrawn
  • ULS de Trás-os-Montes e Alto Douro · Vila Real, PortugalRecruiting→Withdrawn
Show 8 added (8 Japan)
  • Itami City Hospital · Itami, Japan
  • Seirei Mikatahara General Hospital · Hamamatsu, Japan
  • Tanaka Neurosurgery & Headache Clinic · Kagoshima, Japan
  • Hiroshima University Hospital · Hiroshima, Japan
  • Kyoto University Hospital · Kyoto, Japan
  • National Hospital Organization Nishiniigata Chuo Hospital · Niigata, Japan
  • Tokushima University Hospital · Tokushima, Japan
  • Institute of Science Tokyo Hospital · Tokyo, Japan
across 2 updates, Oct 8, 2026 – Nov 2, 2026
Primary completion
Oct 2026→Jan 2028
Oct 8, 2026
Study completion
Dec 2026→Mar 2028
Oct 8, 2026
Show all 2 updates
  1. Nov 2, 2026
    5 sites added
    Show 5 added (5 Japan)
    • Hiroshima University Hospital · Hiroshima, Japan
    • Kyoto University Hospital · Kyoto, Japan
    • National Hospital Organization Nishiniigata Chuo Hospital · Niigata, Japan
    • Tokushima University Hospital · Tokushima, Japan
    • Institute of Science Tokyo Hospital · Tokyo, Japan
  2. Oct 8, 2026
    3 sites added — first site in Japan. 4 sites changed recruiting status (4 now withdrawn)
    Show 4 sites
    • Clinical Trials, Inc. · Little Rock, United StatesRecruiting→Withdrawn
    • Rancho Research Institute · Downey, United StatesRecruiting→Withdrawn
    • Università degli studi di Bari Aldo Moro · Bari, ItalyRecruiting→Withdrawn
    • ULS de Trás-os-Montes e Alto Douro · Vila Real, PortugalRecruiting→Withdrawn
    Show 3 added (3 Japan)
    • Itami City Hospital · Itami, Japan
    • Seirei Mikatahara General Hospital · Hamamatsu, Japan
    • Tanaka Neurosurgery & Headache Clinic · Kagoshima, Japan
    Primary completion Oct 2026→Jan 2028
    Study completion Dec 2026→Mar 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05716100
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
May 9, 2023
Primary completion
Jan 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Xenon Medical Affairs
Contact
XenonCares@xenon-pharma.com
1-604-484-3300
Xenon Medical Director
study director · Xenon Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion